NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $0.61 +0.00 (+0.63%) As of 08/1/2025 03:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock About MetaVia Stock (NASDAQ:MTVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MetaVia alerts:Sign Up Key Stats Today's Range$0.60▼$0.6150-Day Range$0.61▼$0.7952-Week Range$0.60▼$4.32Volume33,926 shsAverage Volume59,308 shsMarket Capitalization$11.93 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingBuy Company Overview MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Read More Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Email Address MTVA Stock News HeadlinesMetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...July 10, 2025 | finanznachrichten.deMetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trialJuly 10, 2025 | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated DoseJuly 9, 2025 | prnewswire.comOTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCRJune 27, 2025 | msn.comMTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…June 24, 2025 | finance.yahoo.comMetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific SessionJune 21, 2025 | prnewswire.comMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | financialpost.comFSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $2.03 at the beginning of the year. Since then, MTVA shares have decreased by 70.0% and is now trading at $0.6090. How were MetaVia's earnings last quarter? MetaVia Inc. (NASDAQ:MTVA) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.21. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2025Today8/03/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTVA CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Price Target for MetaVia$7.50 High Price Target$12.00 Low Price Target$3.00 Potential Upside/Downside+1,131.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-222.13% Return on Assets-123.85% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book0.66Miscellaneous Outstanding Shares19,590,000Free Float19,432,000Market Cap$11.93 million OptionableN/A Beta0.26 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:MTVA) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
